drugset / Trial / NCT06783790
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation with C-KIT mutation RUNX1::RUNX1T1 or CBFB::MYH11.
Timeline
- Start
- 2025-01-20
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avapritinib | Small molecule | 100 mg | Oral |
| Background | Azacitidine | Other / unclassified | 35 mg/m2 | — |
| Background | Venetoclax | Small molecule | 100 mg | Oral |